Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Breast 2

Conditions

Breast Neoplasms 117Stomach Neoplasms 20HER2-positive Breast Cancer 14Neoplasm Metastasis 13Neoplasms 12Colorectal Neoplasms 11Esophageal Neoplasms 9Triple Negative Breast Neoplasms 5Lung Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Meningeal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Inflammatory Breast Neoplasms 3Hematologic Neoplasms 3Gallbladder Neoplasms 3Breast Diseases 3Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

Trastuzumab 4tucatinib 3Capecitabine 3fludarabine 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2sapanisertib 1pertuzumab 1patritumab deruxtecan 1omburtamab I-131 1gadopiclenol 1gadobutrol 1fludarabine phosphate 1avelumab 1aldesleukin 1Spinal Puncture 1Specimen Handling 1Nivolumab 1Methotrexate 1Mesna 1Interleukin-2 1Blood Specimen Collection 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Meningeal Neoplasms × Trastuzumab × 1 year × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Sunnybrook Health Sciences Centre

Phase 2 Recruiting
30 enrolled
Breast

Breast Neoplasms, Meningeal Neoplasms

NCT05800275 2025-11-18

ETIC-LM

UNICANCER

Phase 2 Recruiting
30 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡